PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34875483-8	2022	Therefore, it can be concluded that combination of CTLA-4 blockade with MUC1 mRNA nanovaccine enhances anti-tumor cytotoxic T-lymphocyte activity by reducing immunosuppressive TME and inhibiting tumor-promoting STAT3 signaling pathway.	nanovaccine	82-93	signal transducer and activator of transcription 3	Homo sapiens	211-216	
25457983-0	2015	Nanovaccine loaded with poly I:C and STAT3 siRNA robustly elicits anti-tumor immune responses through modulating tumor-associated dendritic cells in vivo.	nanovaccine	0-11	signal transducer and activator of transcription 3	Homo sapiens	37-42